PPAR dual agonists: Are they opening Pandora's Box?

Pharmacological Research

Volumn 56, Issue 2, 2007, Pages 91-98

  Balakumar, Pitchai ^a   Rose, Madhankumar ^a   Ganti, Subrahmanya S ^b   Krishan, Pawan ^a   Singh, Manjeet ^a,b  

^a PUNJABI UNIVERSITY   (India)

^b ISF Institute of Pharmaceutical Sciences and Drug Research   (India)

Author keywords

Diabetic cardiovascular complications; PPAR dual agonists; PPAR pan agonists

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; BEZAFIBRATE; BVT 142; CARBAZOLE DERIVATIVE; CHIGLITAZAR; CINNAMIC ACID DERIVATIVE; CS 038; FARGLITAZAR; GW 625019; GW 677954; HALOFENATE; IMIGLITAZAR; MURAGLITAZAR; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; NAVEGLITAZAR; NETOGLITAZONE; PA 082; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENYLPROPIONIC ACID DERIVATIVE; PIOGLITAZONE; PLX 204; RAGAGLITAZAR; REGLITAZAR; ROSIGLITAZONE; TESAGLITAZAR; UNCLASSIFIED DRUG; Y 818;

ADIPOCYTE; ANEMIA; ANGIOSARCOMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; CREATININE BLOOD LEVEL; DRUG RESEARCH; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LEUKOPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; THERAPY EFFECT; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; UROGENITAL TRACT TUMOR; WEIGHT GAIN; ZUCKER DIABETIC FATTY RAT;

ANIMALS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; TREATMENT OUTCOME;

EID: 34548182594     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.03.002     Document Type: Review

References (96)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the american heart association. Circulation 100 (1999) 1134-1146
3. Huss J.M., and Kelly D.P. Nuclear receptor signaling and cardiac energetics. Circ Res 95 (2004) 568-578
4. Buse J.B. Glitazones and heart failure: critical appraisal for the clinician. Circulation 108 (2003) e57
5. Tenenbaum A., Motro M., and Fisman E.Z. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 4 (2005) 1-5
6. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
7. Barish G.D., Narkar V.A., and Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116 (2006) 590-597
8. Cabrero A., Laguna J.C., and Vazquez M. Peroxisome proliferator-activated receptors and the control of inflammation. Curr Drug Targets Inflamm Allergy 1 (2002) 243-248
9. Blaschke F., Takata Y., Caglayan E., Law R.E., Hsueh W.A., and Obesity. Peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol 26 (2006) 28-40
10. Alvarez de Sotomayor M, Mingorance C, Andriantsitohaina R. Fenofibrate improves age-related endothelial dysfunction in rat resistance arteries. Atherosclerosis 2007; in press.
11. Balakumar P., and Singh M. Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats. Pharmacol 78 (2006) 91-97
12. Balakumar P., and Singh M. Effect of 3-aminobenzamide, an inhibitor of poly (ADPribose) polymerase in experimental cardiac hypertrophy. Int J Pharmacol 2 (2006) 543-548
13. Balakumar P., and Singh M. Possible role of poly (ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy. Meth Find Exp Clin Pharmacol 28 (2006) 683-689
14. Balakumar P., and Singh M. Possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic Clin Pharmacol Toxicol 99 (2006) 418-424
15. Miyauchi T., and Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 61 (1999) 391-415
16. Ritter O., and Neyses L. The molecular basis of myocardial hypertrophy and heart failure. Trends Mol Med 9 (2003) 313-321
17. Balakumar P., and Singh M. Anti-TNF-α therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol 99 (2006) 391-398
18. Balakumar P., Rose M., and Singh M. Peroxisome proliferator activated receptor agonists: emerging therapy for cardiovascular complications. J Pharmacol Toxicol 2 (2007) 205-219
19. Liang F., Wang F., Zhang S., and Gardner D.G. Peroxisome proliferator activated receptor (PPAR) alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology 144 (2003) 4187-4194
20. Ichihara S., Obata K., Yamada Y., Nagata K., Noda A., Ichihara G., et al. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 41 (2006) 318-329
21. Aasum E., Belke D.D., Severson D.L., Riemersma R.A., Cooper M., Andreassen M., et al. Cardiac function and metabolism in type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol 283 (2002) H949-H957
22. Ogata T., Miyauchi T., Sakai S., Irukayama-Tomobe Y., Goto K., and Yamaguchi I. Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci 103 (2002) 284S-288S
23. Ogata T., Miyauchi T., Sakai S., Takanashi M., Irukayama-Tomobe Y., and Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 43 (2004) 1481-1488
24. Wayman N.S., Hattori Y., McDonald M.C., Mota-Filipe H., Cuzzocrea S., Pisano B., et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16 (2002) 1027-1040
25. Yeh C.H., Chen T.P., Lee C.H., Wu Y.C., Lin Y.M., and Lin P.J. Cardiomyocytic apoptosis following global cardiac ischemia and reperfusion can be attenuated by peroxisome proliferator-activated receptor α but not γ activators. Shock 26 (2006) 262-270
26. Israelian-Konaraki Z., and Reaven P.D. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiol Rev 13 (2005) 240-246
27. Tai E.S., Collins D., Robins S.J., O'Connor J.J., Bloomfield H.E., Ordovas J.M., et al. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: The Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 187 (2006) 153-160
28. Kota B.P., Huang T.H., and Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharmacol Res 51 (2005) 85-94
29. Javiya V.A., and Patel J.A. The role of peroxisome proliferator-activated receptors in human disease. Ind J Pharmacol 38 (2006) 243-253
30. Zhang Y.J., Yang X., Kong Q.Y., Zhang Y.F., Chen W.Y., Dong X.Q., et al. Effect of 15d-PGJ2 on the expression of CD40 and RANTES induced by IFN-gamma and TNF-alpha on renal tubular epithelial cells (HK-2). Am J Nephrol 26 (2006) 356-362
31. Wakino S., Kintscher U., Kim S., Yin F., Hsueh W.A., and Law R.E. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1 → S transition in vascular smooth muscle cells. J Biol Chem 275 (2000) 22435-22441
32. Takagi T., Yamamuro A., Tamita K., Yamabe K., Katayama M., Mizoguchi S., et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 146 (2003) E5
33. Benkirane K.F., Amiri Q.N., Diep M., El Mabrouk, and Schiffrin E.L. PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 290 (2006) H390-H397
34. Sidhu J.S., Cowan D., and Kaski J.C. The effects of rosiglitazone, a Peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 42 (2003) 1757-1763
35. Szmitko P.E., Wang C.H., Weisel R.D., de Almeida J.R., Anderson T.J., and Verma S. New markers of inflammation and endothelial cell activation. Circulation 108 (2003) 1917-1923
36. Natali A., Baldeweg S., Toschi E., Capaldo B., Barbaro D., Gastaldelli A., et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 27 (2004) 1349-1357
37. Sidhu J.S., Cowan D., and Kaski J.C. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 94 (2004) 151-156
38. Martens F.M., Rabelink T.J., op't Roodt J., de Koning E.J., and Visseren F.L. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPARgamma agonist pioglitazone. Eur Heart J 27 (2006) 1605-1609
39. Wakino S., Hayashi K., Kanda T., Tatematsu S., Homma K., Yoshioka K., et al. Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res 95 (2004) e45-e55
40. Calnek D.S., Mazzella L., Roser S., Roman J., and Hart C.M. Peroxisome proliferator activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) 52-57
41. Patel C., Wyne K.L., and McGuire D.K. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?. Diab Vasc Dis Res 2 (2005) 61-66
42. Frey N., and Olson E.N. Modulating cardiac hypertrophy by manipulating myocardial lipid metabolism?. Circulation 105 (2002) 1152-1154
43. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
44. Tsuji T., Mizushige K., Noma T., Murakami K., Ohmori K., Miyatake A., et al. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J. Cardiovasc Pharmacol 38 (2001) 868-874
45. Yamamoto K., Ohki R., Lee R.T., Ikeda U., and Shimada K. Peroxisome proliferator activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104 (2001) 1670-1675
46. Diep Q.N., Amiri F., Benkirane K., Paradis P., and Schiffrin E.L. Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. Can J Physiol Pharmacol 82 (2004) 976-985
47. Okada M., Yan S.F., and Pinsky D.J. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J 16 (2002) 1861-1868
48. Molavi B., Chen J., and Mehta J.L. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am J Physiol Heart Circ Physiol 291 (2006) H687-H693
49. Ha K.C. Effect of rosiglitazone on myocardial ischemia-reperfusion injury in rat heart. Korean J Physiol Pharmacol 10 (2006) 181-186
50. Taniguchi Y., Ooie T., Takahashi N., Shinohara T., Nakagawa M., Yonemochi H., et al. Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat. Diabetes 55 (2006) 2371-2378
51. Dormandy J.A., Charbonnel B., Eckland D., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
52. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
53. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
54. Home P.D., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., Dargie H., et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia 48 (2005) 1726-1735
55. Graham T.L., Mookherjee C., Suckling K.E., Palmer C.N., and Patel L. The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis 181 (2005) 29-37
56. Rival Y., Beneteau N., Taillandier T., Pezet M., Dupont-Passelaigue E., Patoiseau J.F., et al. PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435 (2002) 143-151
57. Lee C.H., Chawla A., Urbiztondo N., Liao D., Boisvert W.A., Evans R.M., et al. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302 (2003) 453-457
58. Welch J.S., Ricote M., Akiyama T.E., Gonzalez F.J., and Glass C.K. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFNgamma target genes in macrophages. Proc Natl Acad Sci 100 (2003) 6712-6717
59. Planavila A., Laguna J.C., and Vazquez-Carrera M. Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem 280 (2005) 17464-17471
60. Ding G., Cheng L., Qin Q., Frontin S., and Yang Q. PPARdelta modulates lipopolysaccharide-induced TNF-alpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 40 (2006) 821-828
61. Pourcet B., Fruchart J.C., Staels B., and Glineur C. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 11 (2006) 379-401
62. Etgen G.J., Oldham B.A., Johnson W.T., Broderick C.L., Montrose C.R., Brozinick J.T., et al. The dual peroxisome proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 51 (2002) 1083-1087
63. Fievet C., Fruchart J.C., and Staels B. PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 6 (2006) 606-614
64. Humphries P.S., Almaden J.V., Barnum S.J., Carlson T.J., Do Q.Q.T., Fraser J.D., et al. Pyridine-2-propanoic acids: discovery of dual PPARα/γ agonists as antidiabetic agents. Bioorg Med Chem Lett 16 (2006) 6116-6119
65. Kendall M.D., Rubin C.J., Mohideen P., Ledeine J.M., Belder R., Gross J., et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29 (2006) 1016-1023
66. Mamnoor P.K., Hegde P., Datla S.R., Damarla R.K., Rajagopalan R., and Chakrabarti R. Antihypertensive effect of ragaglitazar: a novel PPARalpha and gamma dual activator. Pharmacol Res 54 (2006) 129-135
67. Chakrabarti R., Misra P., Vikramadithyan R.K., Premkumar M., Hiriyan J., Datla S.R., et al. Antidiabetic and hypolipidemic potential of DRF 2519-a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol 491 (2004) 195-206
68. Verreth W., Ganame J., Mertens A., Bernar H., Herregods M.C., and Holvoet P. Peroxisome proliferator-activated receptor-alpha, gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice. Arterioscler Thromb Vasc Biol 26 (2006) 922-928
69. Carmona M.C., Louche K., Nibbelink M., Prunet B., Bross A., Desbazeille M., et al. Fenofibrate prevents rosiglitazone-induced body weight gain in ob/ob mice. Int J Obes 29 (2005) 864-871
70. Nissen S.E., Wolski K., and Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 (2005) 2581-2586
71. Chira EC, McMillen TS, Wang S, Haw III A, O'Brien KD, Wight TN, et al. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis 2007; in press.
72. Cox S.L. Tesaglitazar: a promising approach in type 2 diabetes. Drugs Today 42 (2006) 139-146
73. Conlon D. Goodbye glitazars?. Br J Diabetes Vasc Dis 6 (2006) 135-137
74. Seber S., Ucak S., Basat O., and Altuntas Y. The effect of dual PPARα/γ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diab Res Clin Prac 71 (2006) 52-58
75. Kasuga J.I., Makishima M., Hashimoto Y., and Miyachi H. Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor α/δ dual agonists. Bioorg Med Chem Lett 16 (2006) 554-558
76. Xu Y., Etgen G.J., Broderick C.L., Canada E., Gonzalez I., Lamar J., et al. Design and synthesis of dual peroxisome proliferator-activated receptors γ and δ agonists as novel euglycemic agents with a reduced weight gain profile. J Med Chem 49 (2006) 5649-5652
77. Hu X., Feng Y., Shen Y., Zhao X.F., Yu J.H., Yang Y.S., et al. Antidiabetic effect of a novel non-thiazolidinedione PPAR γ/α agonist on ob/ob mice. Acta Pharmacol Sin 27 (2006) 1346-1352
78. Xu C., Wang L.L., Liu H.Y., Zhou X.B., Cao T.L., and Li S. C333H, a novel PPARα/γ dual agonist, has beneficial effects on insulin resistance and lipid metabolism. Acta Pharmacol Sin 27 (2006) 223-228
79. Oleksiewicz M.B., Thorup I., Nielsen H.S., Andersen H.V., Hegelund A.C., Iversen L., et al. Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo. Toxicol Pathol 33 (2005) 552-560
80. Egerod F.L., Nielsen H.S., Iversen L., Thorup I., Storgaard T., and Oleksiewicz M.B. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers 10 (2005) 295-309
81. Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC. Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis 2007; in press.
82. Wallace J.M., Schwarz M., Coward P., Houze J., Sawyer J.K., Kelley K.L., et al. Effects of peroxisome proliferator-activated receptor α/δ agonists on HDL-cholesterol in vervet monkeys. J Lipid Res 46 (2005) 1009-1016
83. Ericsson C.G., Nilsson J., Grip L., Svane B., and Hamsten A. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 8 (1997) 1125-1129
84. Elkeles R.S., Diamond J.R., Poulter C., Dhanjil S., Nicolaides A.N., Mahmood S., et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 21 (1998) 641-648
85. Heppner T.J., Bonev A.D., Eckman D.M., Gomez M.F., Petkov G.V., and Nelson M.T. Novel PPARgamma agonists GI 262570 GW 7845 GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. Pharmacology 73 (2005) 15-22
86. Shibata T., Takeuchi S., Yokota S., Kakimoto K., Yonemori F., and Wakitani K. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol 130 (2000) 495-504
87. Nagasawa T., Inada Y., Nakano S., Tamura T., Takahashi T., Maruyama K., et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 536 (2006) 182-191
88. van der Veen J.N., Kruit J.K., Havinga R., Baller J.F., Chimini G., Lestavel S., et al. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res 46 (2005) 526-534
89. Cheng A.Y., and Fantus I.G. Thiazolidinedione-induced congestive heart failure. Ann Pharmacother 38 (2004) 817-820
90. Blasi ER, Heyen J, Hemkens M, McHarg A, Tiwari S, Ecelbarger C. Effects of chronic PPAR-agonist treatment on cardio-renal structure, function, and blood pressure in sprague-dawley rats. J Pharmacol Toxicol Meth 2007; in press.
91. Lipscombe J., Lewis G.F., Cattran D., and Bargman J.M. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 55 (2001) 39-44
92. Kasuga J., Yamasaki D., Araya Y., Nakagawa A., Makishima M., Doi T., et al. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome. Bioorg Med Chem 14 (2006) 8405-8414
93. Gonzalez I.C., Lamar J., Iradier F., Xu Y., Winneroski L.L., York J., et al. Design and synthesis of a novel class of dual PPARγ/δ agonists. Bioorg Med Chem Lett 17 (2007) 1052-1055
94. Allen T., Zhang F., Moodie S.A., Clemens L.E., Smith A., Gregoire F., et al. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes 55 (2006) 2523-2533
95. Burgermeister E., Schnoebelen A., Flament A., Benz J., Stihle M., Gsell B., et al. A novel partial agonist of peroxisome proliferator-activated receptor-γ (PPAR γ) recruits PPAR γ-coactivator-1α, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol Endocrinol 20 (2006) 809-830
96. Tenenbaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., and Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Int Med 165 (2005) 1154-1160